Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,768 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03946878 | Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04171622 | Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | active not recruiting | Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 |
| clinicaltrials |
| NCT04594187 | Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma(MelPORT) | recruiting | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05022446 | The Impact of COVID-19 on Pulmonary Procedures | recruiting | — | 250 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05046080 | Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix | recruiting | — | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05108519 | Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies | recruiting | — | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05114421 | Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05372484 | Rice Technologies for Cervical Cancer Screening and Diagnosis | recruiting | N/A | 678 | M.D. Anderson Cancer CenterOTHER | 2 | Aug 10, 2026 | clinicaltrials |
| NCT05554133 | Precision Optical Guidance for Oral Biopsy | recruiting | N/A | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05674396 | 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial | recruiting | Phase 2 | 108 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05694559 | Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics | recruiting | N/A | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05840484 | Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05879146 | Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06105554 | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06127797 | Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue | recruiting | — | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06207799 | Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06237881 | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06285890 | Phase I Study of HC-7366 for Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06584955 | Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies | active not recruiting | N/A | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06760754 | Examining the Feasibility and Impact of a Clinic-based Food Farmacy and Digital Culinary Medicine Program Among Cancer Survivors Treated in a Safety Net Hospital | recruiting | N/A | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07105020 | iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer | not yet recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03844620 | Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT04765111 | Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05137262 | A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder | active not recruiting | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02861417 | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 204 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04090619 | Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers | active not recruiting | — | 192 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04150939 | Cryoablation for the Treatment of Metastatic Cancer | active not recruiting | N/A | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05055050 | A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630 | active not recruiting | Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05511324 | Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients | active not recruiting | N/A | 124 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06444880 | Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07010315 | Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention | recruiting | — | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07444619 | A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03026062 | Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05144542 | Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer | active not recruiting | N/A | 135 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT01439659 | Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer | active not recruiting | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06358430 | Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) | active not recruiting | Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT02962661 | Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines | suspended | Phase 1 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07234799 | Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers | suspended | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT00633633 | Lifestyle Intervention for Heart Failure | active not recruiting | N/A | 85 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05703854 | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | suspended | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07377526 | TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | suspended | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07633756 | A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy | recruiting | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739745 | Development Of An Endometrial Cancer Educational Tool | not yet recruiting | N/A | 250 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT01134575 | CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01797523 | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03168737 | 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients | active not recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03259503 | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant | completed | Phase 1 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials